Bas W G van Rhijn

Summary

Publications

  1. doi request reprint The FGFR3 mutation is related to favorable pT1 bladder cancer
    Bas W G van Rhijn
    Division of Urology, Princess Margaret Hospital, Toronto, Ontario, Canada
    J Urol 187:310-4. 2012
  2. doi request reprint Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer
    Bas W G van Rhijn
    Division of Urology, University Health Network, Princess Margaret Hospital, Toronto, ON, Canada
    BJU Int 110:1169-76. 2012
  3. doi request reprint Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer
    Bas W G van Rhijn
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Eur Urol 58:433-41. 2010
  4. doi request reprint Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer
    Bas W G van Rhijn
    Department of Urology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Urol Oncol 30:518-23. 2012
  5. doi request reprint Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy
    Bas W G van Rhijn
    Department of Surgical Oncology, Division of Urology, University of Toronto, UHN, Toronto, Ontario, Canada
    Eur Urol 56:430-42. 2009
  6. ncbi request reprint Surveillance with microsatellite analysis of urine in bladder cancer patients treated by radiotherapy
    Bas W G van Rhijn
    Department of Pathology, Erasmus MC Josephine Nefkens Institute, P O Box 1738, 3000 DR, Rotterdam, The Netherlands
    Eur Urol 43:369-73. 2003
  7. ncbi request reprint Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome
    Bas W G van Rhijn
    Department of Pathology, Josephine Nefkens Institute, Erasmus University, Rotterdam, The Netherlands
    J Clin Oncol 21:1912-21. 2003
  8. doi request reprint A new and highly prognostic system to discern T1 bladder cancer substage
    Bas W G van Rhijn
    Department of Surgical Oncology, Division of Urology, University Health Network, Princess Margaret Hospital, Toronto, Canada
    Eur Urol 61:378-84. 2012
  9. ncbi request reprint FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma
    Bas W G van Rhijn
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, 3000 DR Rotterdam, The Netherlands
    Cancer Res 64:1911-4. 2004
  10. doi request reprint Pathological stage review is indicated in primary pT1 bladder cancer
    Bas W G van Rhijn
    Department of Surgical Oncology, Mount Sinai Hospital, Toronto, Canada
    BJU Int 106:206-11. 2010

Collaborators

Detail Information

Publications25

  1. doi request reprint The FGFR3 mutation is related to favorable pT1 bladder cancer
    Bas W G van Rhijn
    Division of Urology, Princess Margaret Hospital, Toronto, Ontario, Canada
    J Urol 187:310-4. 2012
    ..We determined the frequency of FGFR3 mutations and P53 alterations in patients with pT1 bladder cancer and correlated these data to histopathological variables and clinical outcomes...
  2. doi request reprint Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer
    Bas W G van Rhijn
    Division of Urology, University Health Network, Princess Margaret Hospital, Toronto, ON, Canada
    BJU Int 110:1169-76. 2012
    ..Future studies may lead to the incorporation of sub-stage (T1m/T1e) in the TNM classification system for urinary BC to guide clinical decision-making in T1 BC...
  3. doi request reprint Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer
    Bas W G van Rhijn
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Eur Urol 58:433-41. 2010
    ..Molecular grade (mG) based on fibroblast growth factor receptor 3 (FGFR3) gene mutation status and MIB-1 expression was proposed as an alternative to pathologic grade in bladder cancer (BCa) [1]...
  4. doi request reprint Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer
    Bas W G van Rhijn
    Department of Urology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Urol Oncol 30:518-23. 2012
    ..One of the reasons may be that reproducibility of prognostic (clinical and molecular) markers in NMI-BC has been understudied...
  5. doi request reprint Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy
    Bas W G van Rhijn
    Department of Surgical Oncology, Division of Urology, University of Toronto, UHN, Toronto, Ontario, Canada
    Eur Urol 56:430-42. 2009
    ..This review focuses on the prediction of recurrence and progression in non-muscle invasive bladder cancer (NMIBC) and the treatments advocated for this disease...
  6. ncbi request reprint Surveillance with microsatellite analysis of urine in bladder cancer patients treated by radiotherapy
    Bas W G van Rhijn
    Department of Pathology, Erasmus MC Josephine Nefkens Institute, P O Box 1738, 3000 DR, Rotterdam, The Netherlands
    Eur Urol 43:369-73. 2003
    ....
  7. ncbi request reprint Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome
    Bas W G van Rhijn
    Department of Pathology, Josephine Nefkens Institute, Erasmus University, Rotterdam, The Netherlands
    J Clin Oncol 21:1912-21. 2003
    ..We investigated the relationship between FGFR3 status and three molecular markers (MIB-1, P53, and P27kip1) associated with worse prognosis and determined the reproducibility of pathologic grade and molecular variables...
  8. doi request reprint A new and highly prognostic system to discern T1 bladder cancer substage
    Bas W G van Rhijn
    Department of Surgical Oncology, Division of Urology, University Health Network, Princess Margaret Hospital, Toronto, Canada
    Eur Urol 61:378-84. 2012
    ..Management of T1 bladder cancer (BCa) is controversial...
  9. ncbi request reprint FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma
    Bas W G van Rhijn
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, 3000 DR Rotterdam, The Netherlands
    Cancer Res 64:1911-4. 2004
    ..e., FGFR3 mutations were found in low-stage/-grade tumors and were associated with a favorable disease course, whereas P53 alterations were tied to adverse disease parameters...
  10. doi request reprint Pathological stage review is indicated in primary pT1 bladder cancer
    Bas W G van Rhijn
    Department of Surgical Oncology, Mount Sinai Hospital, Toronto, Canada
    BJU Int 106:206-11. 2010
    ..To evaluate the effect of a pathology review on the clinical outcome of patients with primary pT1 bladder cancer (BC), as the clinical course of such patients is variable...
  11. doi request reprint Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors
    Sultan S Alkhateeb
    Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    J Urol 184:81-6. 2010
    ..We examined this issue by comparing the prognosis of primary vs nonprimary T1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin...
  12. doi request reprint The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading
    Bas W G van Rhijn
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Eur Urol 57:1052-7. 2010
    ..A new grading system for bladder cancer (BCa) was adopted in 2004 to reduce observer variability and provide better prognostic information...
  13. doi request reprint Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment
    David M Kakiashvili
    Department of Surgical Oncology Division of Urology, Princess Margaret Hospital, Mount Sinai Hospital, University of Toronto, Ontario, Canada
    BJU Int 107:540-6. 2011
    ..To report the long-term results of bacille Calmette-Guérin (BCG) intravesical therapy in relation to disease progression and recurrence in primary T1 high-grade (HG) bladder cancer (BC) confirmed by central pathological review...
  14. ncbi request reprint Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine
    Bas W G van Rhijn
    Department of Pathology, Josephine Nefkens Institute, Erasmus University, 3000 CA Rotterdam, The Netherlands
    Clin Cancer Res 9:257-63. 2003
    ..We investigated the feasibility of combining microsatellite analysis (MA) and the FGFR3 status for the detection of UCC in voided urine...
  15. pmc FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy
    Lucie C Kompier
    Department of Pathology, Erasmus MC, Rotterdam, The Netherlands
    PLoS ONE 5:e13821. 2010
    ..Tumor specific mutations can be used to detect recurrences in urine assays, presenting a more patient-friendly diagnostic procedure than cystoscopy...
  16. ncbi request reprint A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine
    Johanna M M van Oers
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands
    Clin Cancer Res 11:7743-8. 2005
    ..In this paper, we describe a simple assay for the simultaneous detection of nine different FGFR3 mutations...
  17. doi request reprint Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial
    Madelon N M van der Aa
    Department of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    J Urol 183:76-80. 2010
    ..We evaluated the influence of knowledge of urine test outcome on the accuracy of cystoscopy (diagnostic review bias) during surveillance in patients with low grade, nonmuscle invasive urothelial carcinoma...
  18. ncbi request reprint Frequent FGFR3 mutations in urothelial papilloma
    Bas W G van Rhijn
    Department of Pathology, Josephine Nefkens Institute, Erasmus University, 3000 DR Rotterdam, The Netherlands
    J Pathol 198:245-51. 2002
    ....
  19. ncbi request reprint Urine markers for bladder cancer surveillance: a systematic review
    Bas W G van Rhijn
    Department of Urology, University Hospital, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Eur Urol 47:736-48. 2005
    ..Therefore, we reviewed the literature on these markers for recurrent UCC and compared our findings with recent review-articles...
  20. ncbi request reprint Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders
    Bas W G van Rhijn
    Department of Pathology, Josephine Nefkens Institute, Erasmus University, 3000 DR Rotterdam, The Netherlands
    Eur J Hum Genet 10:819-24. 2002
    ..From a clinical perspective, the patients with FGFR3-related, non-lethal skeletal disorders might be at a higher risk for development of bladder tumours than the general population...
  21. doi request reprint (18)F-fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography Aids Staging and Predicts Mortality in Patients With Muscle-invasive Bladder Cancer
    Laura S Mertens
    Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands Electronic address
    Urology 83:393-9. 2014
    ..To investigate the association between extravesical (18)F-fluorodeoxyglucose (FDG) avid lesions on FDG-positron emission tomography/computed tomography (PET/CT) and mortality in patients with muscle-invasive bladder cancer...
  22. doi request reprint FDG-positron emission tomography/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer
    Laura S Mertens
    Department of Urology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    J Urol 189:1687-91. 2013
    ..We evaluated FDG-positron emission tomography/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer. We compared this to contrast enhanced computerized tomography...
  23. doi request reprint Optimal timing of radical cystectomy in T1 high-grade bladder cancer
    Peter J Bostrom
    Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada
    Expert Rev Anticancer Ther 10:1891-902. 2010
    ....
  24. doi request reprint BCAN Think Tank session 1: Overview of risks for and causes of bladder cancer
    Alexandre R Zlotta
    Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital and the University Health Network, Mt Sinai Hospital, University of Toronto, Ontario, Canada
    Urol Oncol 28:329-33. 2010
    ..Given the costs associated with the treatment and surveillance of bladder cancer, a comprehensive program supported by governmental funding sources to identify the risks associated with bladder cancer development would seem prudent...
  25. doi request reprint Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?
    Laura S Mertens
    Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    J Urol 188:1108-13. 2012
    ..A comparison was made with patients who received induction cisplatin based combination chemotherapy...